樂
樂觀
樂觀 · 25%AKYA
$1.21
情境價格
$1.290
-0.066 (-5.15%)收盤時
Loading chart…
- 最高
- 1.640
- 開盤
- 1.410
- 成交量加權均價
- 1.41
- 成交量
- 715.25K
- 市值
- 120.50M
- 最低
- 1.290
- 成交金額
- 1.01M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -7.63
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
估值指標
Akoya Biosciences Inc（AKYA）目前預期本益比為 -2.50，5 年平均預期本益比為 -5.33。
Alphio AI 對 AKYA 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
8.505-23NewsfilterKent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
9.005-23PRnewswireNew Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
8.505-21SeekingAlphaAkoya surges as unsolicited buyout offer risks Quanterix merger
7.004-28Globenewswire$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AKYA, WTMA, PLYA, QTRX to Act Now
7.004-24GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PPBI, SSBK, AKYA on Behalf of Shareholders
AKYA 常見問題 —— 由 Alphio AI 解答
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。